compound introduction
Evifacotrep, a short transient receptor potential channel 5 and 4 ( TRPC5 / TRPC4 ) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases. Evifacotrep targets to TRPC5 / TRPC4 with IC 50 s ≤50 nM In Vitro Evifacotrep (1 μM; 24 h) inhibits cell growth in ICLN-1694 cells(HEK-TRExhTRPC4). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Evifacotrep (30 mg/kg; sc; once daily or twice daily for 10 days) results in reduced urinary albumin excretion on following injury with puromycinaminonucleoside (PAN) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:TRPC5
